<DOC>
	<DOCNO>NCT02110147</DOCNO>
	<brief_summary>This protocol two part - Main Study 42 day length Treatment Extension Study allow patient complete Main Study continue receive treatment uridine triacetate . The purpose study replace oral administration uridine oral administration uridine triacetate patient hereditary orotic aciduria receive ( would reasonably expect receive ) clinical benefit treatment exogenous uridine . It also document continued clinical benefit exogenous uridine patient switch oral administration uridine oral administration uridine triacetate .</brief_summary>
	<brief_title>Open-Label Study Uridine Triacetate Pediatric Patients With Hereditary Orotic Aciduria</brief_title>
	<detailed_description>Data collect Main Study include demographic , baseline disease information medical history include prior disease-directed therapy . In addition , vital sign , laboratory value adverse event information collect record . Urine sample obtain measure orotic acid orotidine level . Systemic level uridine evaluate plasma sample collect set timepoints . Upon successful completion Main Study entry Treatment Extension study , physical exam vital sign perform every six ( 6 ) month . Additionally , plasma sample measure systemic level uridine urine sample measure level orotic acid orotidine collect every ( 6 ) six month .</detailed_description>
	<mesh_term>Purine-Pyrimidine Metabolism , Inborn Errors</mesh_term>
	<criteria>Inclusion Criteria ( Main Study ) : Age equal less 19 year Patients diagnose hereditary orotic aciduria Judged investigator initiative mean compliant protocol Able take oral medication Able provide write informed consent ( patient legally authorize representative ) Females childbearing potential must negative pregnancy test screening Females childbearing potential male partner childbearing potential use one follow acceptable birth control method : Surgically sterile partner surgically sterile Using adequate contraception ( hormonal contraceptive , double barrier method , intrauterine device ) Patients claim sexually inactive agree use acceptable method contraception become sexually active 14 day prior first dosing , throughout study 14 day last dose administration Exclusion Criteria ( Main Study ) : Has know allergy uridine triacetate excipients Known ornithine transcarbamoylase deficiency Unable initiative mean compliant protocol Unable compliant take oral medication Unable provide write informed consent ( patient legally authorize representative ) Female pregnant lactate Inclusion Criteria ( Treatment Extension ) Patient successfully complete Main Study Exclusion Criteria ( Treatment Extension Study ) Patient successfully complete Main Study</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>